Syros Pharmaceuticals, Inc. is not engaged in any business activities. The Company is actively engaged in the voluntary delisting process. The Company was previously engaged in developing new standards of care for the frontline treatment of patients with hematologic malignancies.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	6.17M 5.31M 4.98M 4.56M 8.5M 583M 8.57M 58.89M 22.94M 298M 23.15M 22.65M 959M	P/E 2022	-0.48x	P/E 2023	-1.34x
Enterprise Value	-71.28M -61.33M -57.56M -52.66M -98.29M -6.74B -99.06M -681M -265M -3.44B -268M -262M -11.09B	EV / Sales 2022	-4.44x	EV / Sales 2023	12.6x
Free-Float	99.93%	Yield 2022 *	-	Yield 2023	-

24/03/25	Syros Pharmaceuticals, Inc.(OTCPK:SYRS) dropped from S&P TMI Index	CI
19/03/25	Syros Pharmaceuticals, Inc.(OTCPK:SYRS) dropped from NASDAQ Composite Index	CI
01/03/25	Syros Pharmaceuticals to Delist from Nasdaq, Deregister Common Shares	MT
01/03/25	Syros Pharmaceuticals, Inc. Announces Cessation of Gerald Quirk as Chief Executive Officer, Effective March 01, 2025	CI
01/03/25	Syros Pharmaceuticals, Inc. Announces Management Changes	CI
23/12/24	Syros Pharmaceuticals, Inc.(NasdaqGS:SYRS) dropped from S&P Global BMI Index	CI
13/11/24	Brookline Capital Downgrades Syros Pharmaceuticals to Hold	MT
13/11/24	TD Cowen Downgrades Syros Pharmaceuticals to Hold	MT
13/11/24	JMP Securities Downgrades Syros Pharmaceuticals to Market Perform	MT
13/11/24	HC Wainwright Downgrades Syros Pharmaceuticals to Neutral, $1 Price Target	MT
13/11/24	Syros Pharmaceuticals, Inc. Announces Event of Default Occurred Under the Loan and Security Agreement with Oxford Finance LLC	CI
13/11/24	Syros Pharmaceuticals Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression	CI
31/10/24	Syros Pharmaceuticals, Inc., Q3 2024 Earnings Call, Oct 31, 2024

13/11/24	Brookline Capital Downgrades Syros Pharmaceuticals to Hold	MT
13/11/24	TD Cowen Downgrades Syros Pharmaceuticals to Hold	MT
13/11/24	JMP Securities Downgrades Syros Pharmaceuticals to Market Perform	MT
13/11/24	HC Wainwright Downgrades Syros Pharmaceuticals to Neutral, $1 Price Target	MT
11/05/23	JMP Securities Adjusts Price Target on Syros Pharmaceuticals to $15 From $16, Maintains Market Outperform Rating	MT

01/03/25	Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration	BU
18/11/24	Syros Pharmaceuticals : Management Change/Compensation Form 8 K	PU
13/11/24	Syros Pharmaceuticals : Announces Topline Data from SELECT MDS 1 Phase 3 Trial of Tamibarotene in Higher Risk Myelodysplastic Syndrome with RARA Gene Overexpression Form 8 K	PU
13/11/24	Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression	BU
01/11/24	Syros Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides a Business Update	AQ

24/07/23	USA-Les valeurs à suivre à Wall Street (actualisé)
06/08/21	Bourse Zurich: le SMI termine dans le vert juste sous les 12'200 points
05/08/21	Roche signe un accord de livraison avec Syros Pharmaceuticals

Syros Pharmaceuticals Inc Stock Cinnober Boat

Stocks

0LC7

US87184Q1076

Biotechnology & Medical Research

Valuation : Syros Pharmaceuticals Inc

Latest news : Syros Pharmaceuticals Inc

Analysts' recommendations : Syros Pharmaceuticals Inc

Press Releases : Syros Pharmaceuticals Inc

News in other languages : Syros Pharmaceuticals Inc

Managers and Directors : Syros Pharmaceuticals Inc

Other Biotechnology & Medical Research

Financials

Company Profile

Manager	Title	Age	Since
Gerald Quirk CEO	Chief Executive Officer	58	22/11/2024
Karen Hunady IRC	Investor Relations Contact	-	01/10/2022
Matthew Foster PRN	Corporate Officer/Principal	-	01/03/2025

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SYROS PHARMACEUTICALS INC	-.--%	-.--%	-	-	10.73K
LONZA GROUP AG	-0.24%	-1.09%	+2.00%	+17.50%	50.14B
REVOLUTION MEDICINES, INC.	+0.93%	-4.85%	+429.12%	+524.61%	44.85B
IQVIA HOLDINGS INC.	+2.64%	+3.05%	+46.46%	+22.41%	43.43B
BEONE MEDICINES AG	-0.06%	-2.83%	+7.64%	+76.70%	41.14B
CELLTRION, INC.	+0.43%	-3.26%	+14.75%	+49.08%	32.92B
ASCENDIS PHARMA A/S	+1.34%	+8.25%	-	-	17.56B
MEDPACE HOLDINGS, INC.	-0.19%	-3.06%	+23.19%	+123.63%	16.55B
EUROFINS SCIENTIFIC SE	+0.93%	+0.88%	+19.64%	+29.70%	14.65B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+0.39%	-0.91%	+80.93%	+43.77%	13.93B
Average	+0.58%	-0.77%	+77.97%	+110.92%	30.57B
Weighted average by Cap.	+0.65%	-1.13%	+93.02%	+129.04%

	2022	2023
Net sales	14.88M 12.8M 12.01M 10.99M 20.52M 1.41B 20.68M 142M 55.35M 719M 55.88M 54.66M 2.32B	9.94M 8.55M 8.02M 7.34M 13.7M 939M 13.81M 94.9M 36.96M 480M 37.31M 36.5M 1.55B
Net income	-94.65M -81.44M -76.43M -69.92M -131M -8.95B -132M -904M -352M -4.57B -355M -348M -14.73B	-165M -142M -133M -122M -227M -15.56B -229M -1.57B -612M -7.95B -618M -605M -25.61B
Net Debt	-139M -119M -112M -102M -191M -13.11B -193M -1.33B -516M -6.7B -521M -510M -21.58B	-77.45M -66.64M -62.54M -57.21M -107M -7.32B -108M -740M -288M -3.74B -291M -285M -12.05B